RecruitingPhase 1NCT06868849

A Study of JMT203 in Patients With Cancer Cachexia

An Open-label, Multi-center, Phase I Study to Investigate Safety, Tolerability, Pharmacokinetics, and Efficacy of JMT203 in Patients With Cancer Cachexia

Sponsor

Shanghai JMT-Bio Inc.

Enrollment

130 participants

Start Date

May 15, 2024

Study Type

INTERVENTIONAL

Conditions

Colorectal, Cancer Pancreatic Cancer Non-small Cell Lung Cancer Cancer Cachexia

Summary

This is an open-label, multicenter Phase I clinical study aimed at evaluating the safety/tolerability, pharmacokinetics, and effectiveness of JMT203 in patients with cancer cachexia.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a new drug called JMT203 to help people with cancer who are experiencing severe, unintended weight loss and muscle wasting — a condition called cancer cachexia. The drug aims to improve nutrition and quality of life alongside ongoing cancer treatment. **You may be eligible if...** - You are 18 years old or older - You have a confirmed solid tumor cancer (such as lung, pancreatic, or colorectal cancer) - You have lost more than 5% of your body weight in the past 6 months without trying, or more than 2% if your BMI is below 18.5 - Your cancer treatment has been stable with no major changes recently **You may NOT be eligible if...** - Your cancer has been progressing quickly and your treatment plan is expected to change soon - You do not meet the weight loss criteria for cancer cachexia - You are not willing to participate or cannot sign the consent form Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGJMT203 Injection

Drug：JMT203 Injection * Anti-GFRAL monoclonal antibody * Will be injected subcutaneously once per cycle (3 weeks, on Day 1) for 12 weeks, or will be injected subcutaneously once per cycle (3 weeks, on Day 1).